Javaid Iqbal1, Eitan Amir2, Paula A Rochon3, Vasily Giannakeas4, Ping Sun1, Steven A Narod5. 1. Women's College Research Institute, Women's College Hospital, Breast Cancer Research, University of Toronto, Toronto, Ontario, Canada. 2. Institute of Health Policy, Management and Evaluation, Department of Medicine, University of Toronto, Toronto, Ontario, Canada3Cancer Clinical Research Unit, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada. 3. Women's College Research Institute, Women's College Hospital, Breast Cancer Research, University of Toronto, Toronto, Ontario, Canada2Institute of Health Policy, Management and Evaluation, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. 4. Women's College Research Institute, Women's College Hospital, Breast Cancer Research, University of Toronto, Toronto, Ontario, Canada4Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada. 5. Women's College Research Institute, Women's College Hospital, Breast Cancer Research, University of Toronto, Toronto, Ontario, Canada5Dalla Lana School of Public Health, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Abstract
IMPORTANCE: Increasing numbers of women experience pregnancy around the time of, or after, a diagnosis of breast cancer. Understanding the effect of pregnancy on survival in women with breast cancer will help in the counseling and treatment of these women. OBJECTIVE: To compare the overall survival of women diagnosed with breast cancer during pregnancy or in the postpartum period with that of women who had breast cancer but did not become pregnant. DESIGN, SETTING, AND PARTICIPANTS: This population-based, retrospective cohort study linked health administrative databases in Ontario, Canada, comprising 7553 women aged 20 to 45 years at the time of diagnosis with invasive breast cancer, from January 1, 2003, to December 31, 2014. EXPOSURES: Any pregnancy in the period from 5 years before, until 5 years after, the index date of the diagnosis of breast cancer. Women were classified into the following 4 exposure groups: no pregnancy (the referent), pregnancy before breast cancer, pregnancy-associated breast cancer, and pregnancy following breast cancer. MAIN OUTCOMES AND MEASURES: Five-year actuarial survival rates for all exposure groups, age-adjusted and multivariable hazard ratios [HRs] of pregnancy for overall survival for all exposure groups, and time-dependent hazard ratios for women with pregnancy following breast cancer. RESULTS: Among the 7553 women in the study (mean age at diagnosis, 39.1 years; median, 40 years; range, 20-44 years) the 5-year actuarial survival rate was 87.5% (95% CI, 86.5%-88.4%) for women with no pregnancy, 85.3% (95% CI, 82.8%-87.8%) for women with pregnancy before breast cancer (age-adjusted hazard ratio, 1.03; 95% CI, 0.85-1.27; P = .73), and 82.1% (95% CI, 78.3%-85.9%) for women with pregnancy-associated breast cancer (age-adjusted hazard ratio, 1.18; 95% CI, 0.91-1.53; P = .20). The 5-year actuarial survival rate was 96.7% (95% CI, 94.1%-99.3%) for women who had pregnancy 6 months or more after diagnosis of breast cancer, vs 87.5% (95% CI, 86.5%-88.4%) for women with no pregnancy) (age-adjusted HR, 0.22; 95% CI, 0.10-0.49; P < .001). CONCLUSIONS AND RELEVANCE: Pregnancy did not adversely affect survival in women with breast cancer. For breast cancer survivors who wish to conceive, the risk of death is lowest if pregnancy occurs 6 months or more after diagnosis.
IMPORTANCE: Increasing numbers of women experience pregnancy around the time of, or after, a diagnosis of breast cancer. Understanding the effect of pregnancy on survival in women with breast cancer will help in the counseling and treatment of these women. OBJECTIVE: To compare the overall survival of women diagnosed with breast cancer during pregnancy or in the postpartum period with that of women who had breast cancer but did not become pregnant. DESIGN, SETTING, AND PARTICIPANTS: This population-based, retrospective cohort study linked health administrative databases in Ontario, Canada, comprising 7553 women aged 20 to 45 years at the time of diagnosis with invasive breast cancer, from January 1, 2003, to December 31, 2014. EXPOSURES: Any pregnancy in the period from 5 years before, until 5 years after, the index date of the diagnosis of breast cancer. Women were classified into the following 4 exposure groups: no pregnancy (the referent), pregnancy before breast cancer, pregnancy-associated breast cancer, and pregnancy following breast cancer. MAIN OUTCOMES AND MEASURES: Five-year actuarial survival rates for all exposure groups, age-adjusted and multivariable hazard ratios [HRs] of pregnancy for overall survival for all exposure groups, and time-dependent hazard ratios for women with pregnancy following breast cancer. RESULTS: Among the 7553 women in the study (mean age at diagnosis, 39.1 years; median, 40 years; range, 20-44 years) the 5-year actuarial survival rate was 87.5% (95% CI, 86.5%-88.4%) for women with no pregnancy, 85.3% (95% CI, 82.8%-87.8%) for women with pregnancy before breast cancer (age-adjusted hazard ratio, 1.03; 95% CI, 0.85-1.27; P = .73), and 82.1% (95% CI, 78.3%-85.9%) for women with pregnancy-associated breast cancer (age-adjusted hazard ratio, 1.18; 95% CI, 0.91-1.53; P = .20). The 5-year actuarial survival rate was 96.7% (95% CI, 94.1%-99.3%) for women who had pregnancy 6 months or more after diagnosis of breast cancer, vs 87.5% (95% CI, 86.5%-88.4%) for women with no pregnancy) (age-adjusted HR, 0.22; 95% CI, 0.10-0.49; P < .001). CONCLUSIONS AND RELEVANCE: Pregnancy did not adversely affect survival in women with breast cancer. For breast cancer survivors who wish to conceive, the risk of death is lowest if pregnancy occurs 6 months or more after diagnosis.
Authors: Hatem A Azim; Luigi Santoro; William Russell-Edu; George Pentheroudakis; Nicholas Pavlidis; Fedro A Peccatori Journal: Cancer Treat Rev Date: 2012-07-09 Impact factor: 12.111
Authors: Frédéric Amant; Gunter von Minckwitz; Sileny N Han; Marijke Bontenbal; Alistair E Ring; Jerzy Giermek; Hans Wildiers; Tanja Fehm; Sabine C Linn; Bettina Schlehe; Patrick Neven; Pieter J Westenend; Volkmar Müller; Kristel Van Calsteren; Brigitte Rack; Valentina Nekljudova; Nadia Harbeck; Michael Untch; Petronella O Witteveen; Kathrin Schwedler; Christoph Thomssen; Ben Van Calster; Sibylle Loibl Journal: J Clin Oncol Date: 2013-04-22 Impact factor: 44.544
Authors: A de la Rochefordiere; B Asselain; F Campana; S M Scholl; J Fenton; J R Vilcoq; J C Durand; P Pouillart; H Magdelenat; A Fourquet Journal: Lancet Date: 1993-04-24 Impact factor: 79.321
Authors: V F Guinee; H Olsson; T Möller; K R Hess; S H Taylor; T Fahey; J V Gladikov; J W van den Blink; F Bonichon; S Dische Journal: Lancet Date: 1994-06-25 Impact factor: 79.321
Authors: Ciara C O'Sullivan; Sheeba Irshad; Zheyu Wang; Zhuojun Tang; Christopher Umbricht; Gary L Rosner; Mindy S Christianson; Vered Stearns; Karen Lisa Smith Journal: Breast Cancer Res Treat Date: 2020-03-11 Impact factor: 4.872
Authors: J Alejandro Rauh-Hain; Jose Zubizarreta; Roni Nitecki; Alexander Melamed; Shuangshuang Fu; Kirsten Jorgensen; Paula C Brady; Valerie L Baker; Mariana Chavez-MacGregor; Sharon H Giordano; Nancy L Keating Journal: Cancer Date: 2022-06-29 Impact factor: 6.921
Authors: Regina Matar; Angelena Crown; Varadan Sevilimedu; Shari B Goldfarb; Mary L Gemignani Journal: Ann Surg Oncol Date: 2021-10-28 Impact factor: 4.339
Authors: Katarzyna J Jerzak; Nechama Lipton; Sharon Nofech-Mozes; Dina Boles; Elzbieta Slodkowska; Gregory R Pond; Ellen Warner Journal: Breast Cancer Res Treat Date: 2021-07-27 Impact factor: 4.872